RECBIO-B(02179.HK)

Last Updated 08:00:00
longbridge loading
Company Encyclopedia
View More
name
RECBIO-B
02179.HK
Jiangsu Recbio Technology Co., Ltd., a vaccine company, engages in the research, development, and commercialization of subunit vaccines in the People’s Republic of China. The company develops vaccines for the treatment of cervical cancers, and anal and genital warts, including REC603, a recombinant human papillomavirus (HPV) 9-valent vaccine that is in phase III clinical trial; REC601 and REC602 recombinant HPV bivalent vaccines targeting HPV type 6/11, which are in phase I clinical trials; REC604a, a recombinant HPV quadrivalent vaccine that is in pre-clinical stage; REC604c, a recombinant HPV 9-valent vaccine; and REC604a, a novel adjuvanted recombinant HPV quadrivalent vaccine. It also develops ReCOV, a recombinant bicomponent COVID-19 vaccine candidate that is in Phase II/III trial; REC610, a recombinant shingles vaccine that is in Phase l clinical trial; and REC617, a recombinant influenza quadrivalent vaccine that is in pre-clinical stage. In addition, the company’s vaccine pipeline consists of various pre-clinical stage products for respiratory diseases caused by respiratory syncytial virus (RSV)/ metapneumovirus infection, human cytomegalovirus disease, disease caused by hepatitis B virus infection, and herpes caused by herpes simplex infection.
1.326 T
02179.HKMarket value -Rank by Market Cap -/-

Financial Score

21/01/2026 Update
E
BiotechnologyIndustry
Industry Ranking53/53
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-127.96%E
    • Profit Margin-2246.02%E
    • Gross Margin95.44%A
  • Growth ScoreE
    • Revenue YoY-32.82%E
    • Net Profit YoY-18.49%D
    • Total Assets YoY-23.67%E
    • Net Assets YoY-78.35%E
  • Cash ScoreD
    • Cash Flow Margin-4.49%D
    • OCF YoY-32.82%E
  • Operating ScoreE
    • Turnover0.02E
  • Debt ScoreE
    • Gearing Ratio88.49%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    U.S. Stock Movement Update: Anteris Tech surges 41.74%, Corvus Pharma drops 10.09% attracting attention

    In the past hour, the overall market in the U.S. stock market has shown a clear divergence, with technology stocks and the biopharmaceutical sector performing particularly well. The strong rise of Anteris Tech Global has attracted a significant inflow of funds, while Corvus Pharma has faced notable selling pressure, indicating a polarization of market sentiment. Short-term enthusiasm has increased among small-cap stocks, especially with active performances from individual stocks like Moolec Science and Senmiao Tech, driving fluctuations in related sectors. Overall, the market pace is relatively fast, with funds frequently switching between different themes, leading to increased volatility. The stock with the largest movement in the past hour, Anteris Tech Global, surged by 41.74%, becoming the market's focal point. The stock quickly rose after the opening, attracting a large amount of short-term funds, with sentiment high, seemingly indicating an optimistic outlook for its future prospects. Strong stocks include: 1. Moolec Science SA: up 9.11%, driven by recent market expectations for its new products, with active short-term funds. 2. Senmiao Tech: up 7.75%, performing well against the backdrop of an overall recovery in technology stocks, attracting considerable investor attention. 3. Rezolve AI: up 7.61%, with the company's recent technological advancements igniting market enthusiasm and noticeable fund inflows

    Tracking Unusual Activity·
    Tracking Unusual Activity·

    RECBIO has obtained approval for the CHO cell vaccine expansion

    RECBIO-B announced that it recently received additional approval from the Jiangsu Provincial Drug Administration, expanding the production scope to include recombinant shingles vaccine (CHO cells) and related adjuvant components. This marks a further expansion of the group's research and production capabilities in the field of preventive biological products

    AASTOCKS·
    HK
    02179
    -0.18%
    AASTOCKS·
    HK
    02179
    -0.18%

    "Performance" RECBIO's mid-term loss expands to 341 million RMB

    RECBIO-B announced its interim results for the six months ending in June, with revenue recorded at RMB 10.9 million. The loss widened from RMB 249 million in the same period last year to RMB 341 million, with a loss per share of 71 cents. No dividend is declared

    AASTOCKS·
    HK
    02179
    -0.18%
    AASTOCKS·
    HK
    02179
    -0.18%

    RECBIO-B released its interim results, with a loss attributable to shareholders of 341 million yuan, an increase of 36.7% year-on-year

    According to the Zhitong Finance APP, RECBIO-B released its mid-term performance for 2025, with revenue from continuing operations of RMB 10.899 million, compared to none in the same period last year; the loss attributable to the parent company’s owners was RMB 341 million, an increase of 36.7% year-on-year; basic loss per share was RMB 0.71. The year-on-year increase in revenue was mainly due to income generated from the granting of intellectual property licenses during the period

    Zhitong·
    HK
    02179
    -0.18%
    Zhitong·
    HK
    02179
    -0.18%

    RECBIO-B's targeted issuance of domestic shares has been approved by the China Securities Regulatory Commission

    According to the Zhitong Finance APP, RECBIO-B announced that on July 23, 2025, the company received the China Securities Regulatory Commission's "Approval on Jiangsu RECBIO Biotechnology Co., Ltd. to Issue Stocks to Specific Objects" (CSRC Permit [2025] No. 1506), and the China Securities Regulatory Commission has approved this issuance

    Zhitong·
    HK
    02179
    -0.18%
    Zhitong·
    HK
    02179
    -0.18%
    © 2026 Longbridge｜Disclaimer